Brivaracetam/Brivaracetam Pediatric Dosage Guidelines

Brivaracetam/Brivaracetam is widely used in the treatment of epilepsy in children, especially in the control of partial seizures. Because children have large individual differences in body weight, liver and kidney metabolism, and nervous system maturity, their medication regimen needs to be fully individualized. International guidelines usually recommend setting doses stratified according to weight and adjusting by stages to ensure effective control while minimizing the risk of adverse reactions.

Inin children 1 month to 16 years of age, the starting and maintenance doses of brivaracetam are divided by body weight. For infants and young children weighing less than 11 kg, a starting dose of 0.75 to 1.5 mg/kg twice daily is usually recommended, while the maintenance dose can be increased to 0.75 to 3 mg/kg. As body weight increases, the dosage will be adjusted accordingly. For example, for children weighing between 11 and 20 kg, the recommended starting dose is 0.5 to 1.25 mg/kg twice daily; for children weighing between 20 and 50 kg, the starting dose is 0.5 to 1 mg/kg twice daily, while the maintenance dose is between 0.5 and 2 mg/kg.

When children weigh 50 kg and above, the dose can be set according to adult standards. The general starting dose is 25 to 50 mg twice a day, and the maintenance dose can be adjusted to less than 100 mg twice a day. It is worth noting that it is not advisable to rush to reach the maximum dose in the early stage of treatment, but should be gradually adjusted according to the control of seizures and adverse reactions.

Brivaracetam is also available in an intravenous form for short-term treatment in children who cannot take oral medications. The injection dose is equivalent to the oral dose, and it is recommended to use it under the premise that continuous intravenous administration does not exceed4 days.

When doctors formulate a brivaracetam treatment plan for children, they will take into account various factors such as the type of epilepsy, disease control needs, concomitant medications, and parents' monitoring capabilities. It is recommended to regularly monitor body weight, liver and kidney function, and changes in mood and behavior during medication to ensure safe and effective medication.

Reference materials:https://www.briviact.com/